

## LimmaTech Biologics to be Acquired by Lilly for Next-generation Vaccines Against Common Bacterial Infections

- LimmaTech's self-adjuvating and multi-antigen vaccine platform addresses common bacterial infections that currently cannot be prevented
- Lead program focuses on *Staphylococcus aureus* infection, a common complication of surgical procedures

Schlieren (Zurich), May 26, 2026 – [LimmaTech Biologics AG](#), a Swiss clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced entry into a definitive agreement to be acquired by Lilly.

LimmaTech is developing vaccines against bacterial pathogens for which rising antimicrobial resistance is steadily closing therapeutic options, including *Staphylococcus aureus*, *Neisseria gonorrhoeae*, and *Chlamydia trachomatis*. The company's proprietary platform is designed to generate broad, durable immune responses against complex bacterial targets by targeting the toxins and superantigens that drive disease. LimmaTech's lead program, LTB-SA7, is in Phase 1 development as a vaccine against *S. aureus*, the leading cause of surgical-site infection. The company's preclinical pipeline is pursuing additional bacterial pathogens, including those that drive infertility and other long-term consequences of infection that fall disproportionately on women. A vaccine-led prevention strategy could change the trajectory of diseases that are becoming increasingly difficult to treat.

"Joining Lilly is a powerful next chapter for our science and our team," said **Franz-Werner Haas, LL.D., chief executive officer of LimmaTech**. "Lilly's global development capabilities, manufacturing scale and long-standing commitment to patients with serious disease will enable us to accelerate our lead *Staphylococcus aureus* vaccine and to advance our preclinical gonorrhea and chlamydia programs."

"*Staphylococcus aureus* is among the most consequential bacterial pathogens we face — and one of the hardest to prevent. LimmaTech has pursued a distinctive scientific thesis: that targeting the toxins and superantigens that drive disease, rather than bacterial surface antigens, is the way to solve this problem," said **Daniel M. Skovronsky, M.D., Ph.D., Lilly's chief scientific and product officer, and president, Lilly Research Laboratories**. "As antimicrobial resistance erodes our ability to treat bacterial infections, this platform may help us prevent infections before they occur."

Under the terms of the agreement, Lilly will acquire LimmaTech for up to \$780 million in cash, inclusive of an upfront payment and additional potential payments based upon the achievement of certain clinical and regulatory milestones.

"This transaction recognizes the value created by LimmaTech's team, including its investors, and the opportunity inherent in its technology and pipeline. I am pleased to see the company enter this next chapter with a partner that is well-positioned to build on its foundation and accelerate its impact," said **Staph Leavenworth Bakali, Chairman of the Board of LimmaTech.**

LimmaTech is supported by Moelis & Company UK LLP as financial advisor and Goodwin Procter and Vischer as legal advisors.

### **About LimmaTech Biologics AG**

LimmaTech Biologics is at the forefront of combating the global antimicrobial resistance epidemic based on its track record in vaccine technology and clinical candidate development. The company is leveraging its proprietary self-adjuvanting and multi-antigen vaccine platform alongside additional disease-specific vaccine approaches to prevent increasingly untreatable microbial infections. With decades of expertise and an expanding, robust pipeline, the LimmaTech team is dedicated to generating protective solutions to deliver transformative value worldwide. LimmaTech Biologics is backed by specialist healthcare investors, including Adjuvant Capital, BNP Paribas Asset Management Alts, Novo Holdings REPAIR Impact Fund, and Tenmile. For more information, please visit [www.lmtbio.com](http://www.lmtbio.com).

### **Contacts**

#### **For media enquiries**

Gretchen Schweitzer or Sara Ortiz  
Trophic Communications  
Phone: +49 172 861 8540  
Email: [limmatech@trophic.eu](mailto:limmatech@trophic.eu)

*Research reported in this press release is supported by CARB-X. CARB-X is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under agreement number 75A50122C00028 and by awards from Wellcome (WT224842), the UK Department of Health and Social Care's Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Gates Foundation, Germany's Federal Ministry of Research, Technology and Space (BMFTR), the Novo Nordisk Foundation, Italy's Ministry of Economy and Finance (MEF), Japan's Ministry of Health, the European Commission's DG Health Emergency Preparedness and Response Authority (DG HERA), and KfW Development Bank. The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in HHS, provides support in the form of in-kind services through access to a suite of preclinical services for product development. The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of any CARB-X funders.*